Fluoxetine in Pediatric Body Dysmorphic Disorder

PHASE4CompletedINTERVENTIONAL
Enrollment

43

Participants

Timeline

Start Date

November 30, 2004

Primary Completion Date

April 30, 2012

Study Completion Date

April 30, 2012

Conditions
Body Dysmorphic Disorder
Interventions
DRUG

Fluoxetine

Tablets varying between 10mg and 80mg on a fixed/flexible dosing schedule based on the subjects' weight and side effects score.

DRUG

Placebo

Placebo tablets will be given 1x/day for the duration of the study at a fixed/flexible dosing schedule similar to that for the drug fluoxetine based off of subjects' weight and side effects score.

Trial Locations (2)

10467

Montefiore Medical Center, Albert Einstein College of Medicine, The Bronx

02903

Rhode Island Hospital, Providence

All Listed Sponsors
collaborator

Food and Drug Administration (FDA)

FED

lead

Montefiore Medical Center

OTHER

NCT00245635 - Fluoxetine in Pediatric Body Dysmorphic Disorder | Biotech Hunter | Biotech Hunter